Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Basic Science

1980MO - SENP1 knockdown suppresses tumour progression in lung adenocarcinoma by regulating AAT genes expression

Date

18 Sep 2020

Session

Mini Oral - Basic Science

Topics

Pathology/Molecular Biology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

HONG CHENG

Citation

Annals of Oncology (2020) 31 (suppl_4): S1052-S1064. 10.1016/annonc/annonc295

Authors

H. CHENG, R. Li, F. Wang, X. Yu, F. Wang, Y. Gao, J. Mu, J. He

Author affiliations

  • National Cancer Center/national Clinical Research Center For Cancer/cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1980MO

Background

SUMO specific peptidase 1(SENP1) is an important factor involved in the regulation of small ubiquitin-related modifier (SUMO) modification. Our previous research has shown that SENP1 could be a potential tumour-promoting factor in non-small cell lung cancer (NSCLC). However, its role in tumour progression remains largely unknown. This study aims to characterize the role of SENP1 in lung adenocarcinoma.

Methods

The TCGA database provided us expression profiles of SENP1 and overall survival rates. loss-of-function assays were performed to examine the effect of SENP1 on proliferation, migration and invasion of lung adenocarcinoma cells in vitro and in vivo. Immunoprecipitation (IP), western blot and quantitative real time PCR (qRT-PCR) were carried out to reveal the interrelation between SENP1, SIRT6 and AAT (amino acid transporter) genes signal pathway.

Results

In this study, we found that SENP1 was expressed at high levels in lung adenocarcinoma tissues and advanced TNM stages and was significantly associated with poor prognosis. we also found that SENP1 knockdown inhibited lung adenocarcinoma cell progression in vitro and in vivo. SUMOylation of SIRT6 was also observed in lung adenocarcinoma, and it was reduced by SENP1. SUMOylation of SIRT6 specifically increased its deacetylation of histone H3 on lysine 56 instead of that of lysine 9 (H3K9) in an in vitro model. Mechanistically, we found that knockdown of SENP1 reduced the expression of AAT genes by decreasing H3K56 acetylation through increasing SIRT6 SUMOylation. Moreover, mutation of the SUMOylation sites of Sirt6 reduced its tumour-suppressive effects.

Conclusions

These results revealed that SENP1 promotion of tumour progression in lung adenocarcinoma and its tumour-promoting effects might be attributed to its important role in the regulation of Sirt6 SUMOylation and the expression of AAT genes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The National Natural Science Foundation of China the Beijing Municipal Natural Science Foundation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.